证券代码：688690 证券简称：纳微科技 公告编号：2026-001 苏州纳微科技股份有限公司 2025年年度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、上年度业绩情况 2024 年年度营业收入 78,245.67 万元。 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 经公司财务部门初步测算： 1. 预计 2025 年年度实现营业收入 9.18 亿元至 9.30 亿元，较上年度（法定 披露数据）相比，将增加 1.36 亿元至 1.48 亿元，同比增长 17.32%至 18.86%。 2. 预计 2025 年年度实现归属于母公司所有者的净利润 1.28 亿元至 1.45 亿元，较上年度（法定披露数据）相比，将增加 0.45 亿元至 0.62 亿元，同比增 长 54.51%至 75.03%。 3. 预计 2025 年年度实现扣除非经常性损益后归属母公司所有者的净利润 1.12 亿元至 1.28 亿元，较上年度（法定披露数据）相比， ...

Core Viewpoint - Nanwei Technology announced its 2025 performance forecast, expecting a net profit attributable to the parent company of between 128 million to 145 million yuan, representing a growth of 54.51% to 75.03% compared to the previous year [1] Group 1: Financial Performance - The projected net profit for 2025 is between 128 million to 145 million yuan [1] - This represents a significant increase of 54.51% to 75.03% year-over-year [1] Group 2: Business Strategy and Growth - The company is implementing a "3+2" market development strategy [1] - Core product innovation and quality improvements are driving rapid sales growth in chromatography fillers, chromatography media, and liquid chromatography columns [1] - International business expansion has shown significant results, with overseas revenue increasing by approximately 79% year-over-year [1]

Core Viewpoint - Nanwei Technology (688690) expects to achieve a net profit attributable to shareholders of the parent company between 128 million yuan and 145 million yuan for the fiscal year 2025, representing a year-on-year growth of 54.51% to 75.03% [1] Group 1: Financial Performance - The company's core business in chromatographic fillers and chromatography media products saw a sales revenue increase of approximately 23% [1] - Sales revenue for liquid chromatography columns and sample pre-treatment products experienced an increase of about 32% [1]

Core Viewpoint - The company Nanwei Technology expects significant growth in net profit and revenue for the year 2025 compared to the previous year, indicating strong financial performance and positive outlook for the future [1] Financial Performance - The company anticipates a net profit attributable to shareholders of between 128 million to 145 million yuan for 2025, representing an increase of 45 million to 62 million yuan compared to the previous year, which translates to a year-on-year growth of 54.51% to 75.03% [1] - Expected operating revenue for 2025 is projected to be between 918 million to 930 million yuan, an increase of 136 million to 148 million yuan from the previous year, reflecting a year-on-year growth of 17.32% to 18.86% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 112 million to 128 million yuan, an increase of 46 million to 62 million yuan compared to the previous year, indicating a year-on-year growth of 70.02% to 94.31% [1]

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].

Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [1][7]. Industry Overview - Nanospheres are micron-sized spheres with nanoscale pore structures, characterized by high specific surface area and unique physical and chemical properties. They are widely used in drug delivery, liquid crystal displays, bi separation, medical diagnostics, and optoelectronic materials [2][4]. - The primary materials for nanospheres are classified into natural biomaterials (such as chitosan and collagen) and synthetic polymers (like PLGA and PVA) [2]. Nanosphere Classification - Nanospheres can be categorized based on preparation methods, including ion crosslinking, emulsion-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [4]. Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various polymers. The midstream involves the production and manufacturing of nanospheres, while the downstream applications span drug delivery, bi separation, in vitro diagnostics, LCD spacers, conductive materials, and light diffusion films [5][6]. Market Size - The Chinese nanosphere industry is on a growth trajectory, with a market size expected to reach approximately 4.236 billion yuan in 2024, marking a 5.40% increase from the previous year [1][7]. Key Companies - Suzhou Nanwei Technology Co., Ltd. is recognized as the industry leader, leveraging proprietary technologies for precise control over sphere size and surface properties. In the first three quarters of 2025, the company reported revenues of 671 million yuan, a 22.01% increase year-on-year [8][9]. - Xian Lanyao Technology Co., Ltd. is a leading player in the adsorption separation materials sector, focusing on life sciences. The company reported revenues of 193 million yuan in the first three quarters of 2025, reflecting a 2.20% year-on-year growth [10]. Industry Development Trends 1. **Technological Innovation**: The preparation technology for nanospheres is advancing towards ultra-high precision, functional integration, and green transformation, with a focus on AI-assisted design and biodegradable materials [11]. 2. **Diverse Application Demand**: The biopharmaceutical sector remains the core growth area for nanospheres, with increasing demand in electronic displays and environmental applications, leading to a surge in market demand [12]. 3. **Domestic Substitution**: The market is transitioning from foreign monopoly to rapid growth of local enterprises, with domestic leaders like Nanwei Technology gaining market share due to competitive pricing and technological advantages [12].

证券日报网讯1月9日，纳微科技在互动平台回答投资者提问时表示，公司目前专注于生物制药分离纯化 及色谱分析检测主营业务，没有布局拉曼检测技术领域。 ...

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Core Viewpoint - The article discusses the performance of the Zhongzheng 1000 ETF Enhanced (561280), highlighting its opening price and the performance of its major holdings since its inception on August 31, 2023, which has yielded a return of 57.53% [1]. Group 1: ETF Performance - The Zhongzheng 1000 ETF Enhanced (561280) opened at 1.578 yuan, experiencing a decline of 0.19% [1]. - Since its establishment on August 31, 2023, the fund has achieved a return of 57.53% [1]. - The fund's performance over the past month has been a return of 6.26% [1]. Group 2: Major Holdings - Major stocks in the fund include: - Boqian New Materials, which opened with an increase of 0.68% [1]. - Haoyuan Pharmaceutical, which rose by 0.78% [1]. - Yingjixin, which increased by 0.56% [1]. - Caixun Co., which saw a slight increase of 0.08% [1]. - Jinma Leisure, which rose by 0.41% [1]. - Panjiang Co., which remained unchanged [1]. - Jindawei, which decreased by 0.10% [1]. - Yiyuan Communication, which increased by 0.43% [1]. - Minxin Co., which remained unchanged [1]. - Nami Technology, which rose by 0.34% [1]. [1]

北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2025 年第二次临时股东会 法律意见书 二〇二五年十二月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2025 年第二次临时股东会 法律意见书 致苏州纳微科技股份有限公司： 人员和召集人资格、会议表决程序及表决结果是否符合《公司法》等法律、法规、 规范性文件及《公司章程》、《股东会规则》的规定发表意见，不对会议审议的议 案内容以及该等议案所表述的事实或数据的真实性及 ...